Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinoma.


BACKGROUND Irinotecan is effective in patients with advanced colorectal carcinoma in both first-line and salvage settings but its use can be limited by serious side effects. Amifostine has been shown to reduce the incidence of cisplatin-induced cumulative renal toxicity in patients with advanced ovarian carcinoma and nonsmall cell lung carcinoma. In the… (More)


  • Presentations referencing similar topics